Tempest Therapeutics (TPST) Non-Current Deffered Revenue (2015 - 2016)

Tempest Therapeutics (TPST) posted Non-Current Deffered Revenue of $1.3 million for Q3 2016, down 11.93% sequentially from $1.4 million in Q2 2016.

Tempest Therapeutics (TPST) Non-Current Deffered Revenue (2015 - 2016) Analysis & Trends

Tempest Therapeutics has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $1.3 million in Q3 2016.

Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $1.3 million in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $1.3 million (changed N/A YoY) and the FY2015 annual result came in at $520000.0, changed N/A from the prior year.
Non-Current Deffered Revenue retreated to $1.3 million in Q3 2016 per TPST's latest filing, from $1.4 million in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $1.4 million in Q2 2016 and troughed at $520000.0 in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	220.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	147.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Tempest Therapeutics	4.32 Mn	3.52 Mn	-	-

Download Data